drugset / Trial / NCT04180150
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.
Timeline
- Start
- 2019-11-18
- Primary completion
- 2020-09-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQ-A3334 | Other / unclassified | 1.2 mg | — |
| Background | Entecavir | Small molecule | 0.5 mg | — |